

# Jennifer Kahler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10208135/publications.pdf>

Version: 2024-02-01

10  
papers

654  
citations

1464605

7  
h-index

1762888

8  
g-index

11  
all docs

11  
docs citations

11  
times ranked

1403  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 622-631.	3.2	11
2	Abstract 3095: The development of CPI as a novel, next-generation DNA-targeting payload for ADCs. , 2017, , .		1
3	Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. <i>Clinical Cancer Research</i> , 2016, 22, 383-394.	3.2	21
4	Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care. <i>Blood</i> , 2016, 128, 3522-3522.	0.6	0
5	Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4511-4516.	1.0	21
6	Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4381-4387.	1.0	14
7	Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2092-2097.	1.0	21
8	Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1394-1406.	1.9	171
9	High-Throughput Screening for mTORC1/mTORC2 Kinase Inhibitors Using a Chemiluminescence-Based ELISA Assay. <i>Assay and Drug Development Technologies</i> , 2009, 7, 471-478.	0.6	6
10	Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib. <i>Cancer Research</i> , 2006, 66, 8163-8171.	0.4	388